JP2017526924A5 - - Google Patents

Download PDF

Info

Publication number
JP2017526924A5
JP2017526924A5 JP2017511945A JP2017511945A JP2017526924A5 JP 2017526924 A5 JP2017526924 A5 JP 2017526924A5 JP 2017511945 A JP2017511945 A JP 2017511945A JP 2017511945 A JP2017511945 A JP 2017511945A JP 2017526924 A5 JP2017526924 A5 JP 2017526924A5
Authority
JP
Japan
Prior art keywords
nep
vitro
vitro method
soluble
test sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017511945A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017526924A (ja
JP6661216B2 (ja
Filing date
Publication date
Priority claimed from EP14182846.7A external-priority patent/EP2990800A1/en
Application filed filed Critical
Publication of JP2017526924A publication Critical patent/JP2017526924A/ja
Publication of JP2017526924A5 publication Critical patent/JP2017526924A5/ja
Application granted granted Critical
Publication of JP6661216B2 publication Critical patent/JP6661216B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017511945A 2014-08-29 2015-08-14 心不全予後マーカーとしてのネプリライシン Expired - Fee Related JP6661216B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14182846.7 2014-08-29
EP14182846.7A EP2990800A1 (en) 2014-08-29 2014-08-29 Neprilysin as heartfailure (HF) prognostic marker
PCT/EP2015/068729 WO2016030209A1 (en) 2014-08-29 2015-08-14 Neprilysin as heart failure prognostic marker

Publications (3)

Publication Number Publication Date
JP2017526924A JP2017526924A (ja) 2017-09-14
JP2017526924A5 true JP2017526924A5 (enExample) 2018-09-20
JP6661216B2 JP6661216B2 (ja) 2020-03-11

Family

ID=51421966

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017511945A Expired - Fee Related JP6661216B2 (ja) 2014-08-29 2015-08-14 心不全予後マーカーとしてのネプリライシン

Country Status (11)

Country Link
US (1) US10203341B2 (enExample)
EP (2) EP2990800A1 (enExample)
JP (1) JP6661216B2 (enExample)
CN (1) CN107076758B (enExample)
AU (1) AU2015309112A1 (enExample)
CA (1) CA2959094A1 (enExample)
ES (1) ES2734876T3 (enExample)
MX (1) MX2017002453A (enExample)
RU (1) RU2017109086A (enExample)
SG (1) SG11201701393YA (enExample)
WO (1) WO2016030209A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021090909A1 (ja) * 2019-11-06 2021-05-14 国立大学法人 香川大学 心不全マーカー

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100497386C (zh) * 2001-09-03 2009-06-10 因特里特有限公司 非功能性p2x7受体的抗体及其应用
EP2496942B1 (en) * 2009-11-07 2017-03-22 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP2360280A1 (en) * 2010-02-24 2011-08-24 Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol Genetic marker for the diagnosis of dementia with Lewy bodies
JP2014505259A (ja) * 2011-02-03 2014-02-27 アボット・ラボラトリーズ 慢性心不全における予後診断および診断の方法
RU2672561C2 (ru) * 2012-04-12 2018-11-16 Б.Р.А.Х.М.С Гмбх Прогнозирование нежелательных явлений у пациентов с предполагаемым диагнозом хронической сердечной недостаточности
AU2013304949C1 (en) * 2012-08-24 2020-12-24 Novartis Ag NEP inhibitors for treating diseases characterized by atrial enlargement or remodeling
US20140206632A1 (en) * 2013-01-22 2014-07-24 Singulex, Inc. Endothelin in the Diagnosis of Cardiac Disease
TR201808541T4 (tr) * 2013-02-14 2018-07-23 Novartis Ag Nep (nötr endopeptidaz) inhibitörleri olarak ikame edilmiş bisfenil butanoik fosfonik asit türevleri.
JP6301371B2 (ja) * 2013-02-14 2018-04-11 ノバルティス アーゲー インビボ効力が改善されたｎｅｐ阻害剤としての置換ビスフェニルブタン酸誘導体

Similar Documents

Publication Publication Date Title
Zhou et al. Diagnostic value of neutrophil gelatinase-associated lipocalin for early diagnosis of cardiac surgery-associated acute kidney injury: a meta-analysis
Orasan et al. Hyaluronic acid as a biomarker of fibrosis in chronic liver diseases of different etiologies
JP2012509477A5 (enExample)
Shen et al. Implications of the changes in serum neutrophil gelatinase‐associated lipocalin and cystatin C in patients with chronic kidney disease
BR112014006741A2 (pt) método para monitorização, diagnóstico e/ou prognóstico de lesão renal aguda no estágio inicial
WO2010002911A3 (en) Methods and materials for monitoring myeloma using quantitative mass spetrometry
WO2010038974A3 (ko) 이뮤노글로블린 에이 신증과 티지비엠 신증의 진단용 조성물 및 키트
NO20076656L (no) Forbedrede immunoassay metoder
JP2017524130A5 (enExample)
JP2015519564A5 (enExample)
JP2013533977A5 (enExample)
Kim et al. Noninvasive predictors of nonalcoholic steatohepatitis in Korean patients with histologically proven nonalcoholic fatty liver disease
HRP20151023T1 (hr) Metode za detekciju protutijela na lijekove
JP2017532577A5 (enExample)
JP2017505897A5 (enExample)
Nishikawa et al. A proposed predictive model for advanced fibrosis in patients with chronic hepatitis B and its validation
Gandhi et al. Analysis of BAG3 plasma concentrations in patients with acutely decompensated heart failure
JP2015505371A5 (enExample)
JP2009544971A5 (enExample)
JP2013506837A5 (enExample)
JP2014524583A5 (enExample)
US10557860B2 (en) Circulating pulmonary hypertension biomarker
JP2015528562A5 (enExample)
JP2017526924A5 (enExample)
EP3304086B1 (en) Method for predicting responsiveness to a combination therapy with lenvatinib and everolimus